Focused On-demand Library for Zinc finger MYND domain-containing protein 10

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

O75800

UPID:

ZMY10_HUMAN

Alternative names:

Protein BLu

Alternative UPACC:

O75800; A6NK41; B3KU54; O14570; O75801; Q53FE6; Q8N4R6; Q8NDN6

Background:

Zinc finger MYND domain-containing protein 10, also known as Protein BLu, plays a crucial role in the organization and motility of axonemal structures. It is involved in the pre-assembly of inner and outer dynein arms, essential for the proper building of axonemes for cilia motility. This protein's function is pivotal in ensuring the correct movement and structure of cilia, as suggested by research findings.

Therapeutic significance:

Given its significant role in cilia motility and structure, Zinc finger MYND domain-containing protein 10 is directly associated with Primary Ciliary Dyskinesia, particularly type 22. This condition is characterized by motile cilia abnormalities, leading to severe respiratory infections and potentially situs inversus in Kartagener syndrome. Understanding the role of this protein could pave the way for innovative therapeutic strategies targeting ciliary dysfunctions.